Author:
Mazer C. David,Arnaout Amel,Connelly Kim A.,Gilbert Jeremy D.,Glazer Stephen A.,Verma Subodh,Goldenberg Ronald M.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine
Reference35 articles.
1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015
2. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017
3. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019
4. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy;Perkovic;N Engl J Med,2019
5. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial;Dandona;Lancet Diabetes Endocrinol,2017
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献